HBIO

Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, drug and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. The Company’s products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. Its CMT product family includes the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS and Warner brands. Its Preclinical product family provides a complete platform to assess physiological data from organisms for research ranging from basic research to drug discovery, and drug development services. The Preclinical Product family includes the DSI, Panlab, Hugo Sachs and Buxco brands.

Wall Street analysts forecast HBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HBIO is 2.00 USD with a low forecast of 2.00 USD and a high forecast of 2.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Harvard Bioscience Inc revenue for the last quarter amounts to 20.59M USD, decreased -6.27 % YoY.

Harvard Bioscience Inc. EPS for the last quarter amounts to -0.03 USD, decreased -72.73 % YoY.

Harvard Bioscience Inc (HBIO) has 330 emplpoyees as of December 16 2025.

Today HBIO has the market capitalization of 31.35M USD.